ESBATechSuccess through highly stable antibody fragments
The Company Products & Technologies Publications Career

About ESBATech
People
Intellectual Property
Directions
Contact

Drug Discovery and development

Scientific Publications
PR Contact

Why ESBATech
Positions
To apply

 

ESBATech, a Novartis company


 

ESBATech is a Zurich, Switzerland based company of Novartis and part of the Ophthalmology Disease Area research team of the Novartis Institutes for BioMedical Research (NIBR). ESBATech has proprietary antibody fragment technology and strong expertise in biologics research and development up to clinical Proof-of-Concept.  It couples its capabilities with pathways research, biologics technologies, and other platforms in NIBR and Alcon to develop new and effective treatments for a wide range of sight-threatening eye diseases with high unmet need, including age-related macular degeneration, diabetic retinopathy, uveitis, glaucoma and dry eye.
 

 
 

Novartis

 

 
 
ESBATech
Wagistrasse 12
CH-8952
Zurich-Schlieren
Switzerland

 
Disclaimer
©  ESBATech